Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

New Drugs Have an Established Role in CLL: BCR and BCL2 Inhibitors (Ibrutinib, Idelalisib / Rituximab, Venetoclax +/- Rituximab), New Agents Combos, and Their Effect on OS and PFS

211 views
December 20, 2019
Comments 0
Login to view comments. Click here to Login